AstraZeneca partners with AI firm Absci to develop AI-driven cancer therapeutics, investing $247 million.
Recently, AstraZeneca, renowned for its COVID-19 vaccine development, is now forging a path in cancer treatment through a groundbreaking partnership with Absci, a leading U.S.-based AI biologics company. This collaboration, as reported by Financial Times on December 3, is marked by a significant investment from AstraZeneca, totaling up to $247 million in research, development, and various associated costs.
Revolutionizing Antibody Therapeutics with AI
The central focus of this alliance is the development of a zero-shot generative AI model. This innovative technology stands at the forefront of medical research, aiming to not only generate new antibody therapeutics for cancer treatment but also enhance the effectiveness of existing ones. While the specific cancer types targeted in this venture remain undisclosed, the potential impact of this collaboration could be monumental.
Absci, a pioneer in its field, boasts an impressive capability to screen billions of cells weekly. Their technology rapidly progresses from antibodies to verified lab candidates in just six weeks. This efficiency, combined with AstraZeneca’s expertise, signals a significant acceleration in biologics discovery. Currently, Absci involvement includes 17 active projects, demonstrating its robust contribution to the field.
AstraZeneca’s senior vice-president, Puja Sapra, highlights the transformative role of AI in biologics discovery, enhancing both the speed and success rates, as well as diversifying the range of biologics. Additionally, Absci’s CEO, Sean McClain, confirmed the partnership’s focus on leveraging AstraZeneca’s AI capabilities.